Get started

Otcstocks

Bayer Cuts Dividends to Reduce DebtIn a strategic move to tackle its mounting debt and enhance financial flexibility, Bayer ( OTC:BAYRY ), the German pharmaceutical giant, has announced a significant shift in its dividend policy. The decision, though met with mixed reactions from investors and analysts, underscores the company's commitment to addressing its pressing financial challenges. Facing High Debt and Challenging Cash Flow: Bayer's ( OTC:BAYRY ) decision to amend its dividend policy stems from a pressing need to mitigate its high debt burden and grapple with a challenging free cash flow situation. Chief Executive Bill Anderson emphasized the company's priority to reduce debt and increase flexibility, acknowledging the necessity of the amended dividend policy in achieving these objectives. A Drastic Reduction in Dividends: The scale of the dividend reduction is striking. From 2.40 euros per share in the previous year, Bayer ( OTC:BAYRY ) now proposes a mere 0.11 euro dividend for 2023. This substantial cut reflects the severity of the financial constraints Bayer is contending with and underscores the urgency with which it seeks to address them. Analyst Insights and Investor Reactions: Analysts at Jefferies have characterized Bayer's move as emblematic of the extensive operational and financial challenges confronting the company. They emphasize the need for further significant strategic actions to rectify the balance sheet and restore investor confidence. Investor reactions have been mixed, with some expressing understanding of the company's predicament, while others voice concerns about the implications for shareholder returns and the long-term health of the business. Strategic Imperatives: Job Cuts and Potential Breakup: Bayer's ( OTC:BAYRY ) dividend policy amendment follows a series of strategic maneuvers aimed at stabilizing its financial position and reigniting growth. In January, the company announced job cuts, signaling a commitment to streamline operations and reduce costs. Moreover, Bayer ( OTC:BAYRY ) has been exploring options to potentially dismantle its diverse portfolio, which includes prescription drugs, consumer health products, crop chemicals, and seeds. This strategic evaluation underscores the company's willingness to undertake bold measures to revitalize its performance and buoy its beleaguered share price. Conclusion: Bayer's ( OTC:BAYRY ) decision to revise its dividend policy represents a pivotal moment in its ongoing efforts to navigate choppy financial waters. As the company grapples with high debt, challenging cash flow dynamics, and analyst scrutiny, its strategic imperatives underscore a commitment to reshaping its business for sustained success. The road ahead may be fraught with challenges, but Bayer's ( OTC:BAYRY ) willingness to confront them head-on signals a determination to emerge stronger and more resilient in the face of adversity.
OTC:BAYRYLong
by DEXWireNews
Xiaomi's Internet Business Arm Expands PartnershipXiaomi's Internet Business Arm Expands Partnership with Digital Turbine to Power Global App Recommendations. The partnership expansion is the next step in Digital Turbine and Xiaomi's relationship, elevating the quality of app recommendations to Xiaomi smartphone end users around the world. Digital Turbine, the company that connects the mobile ecosystem through innovative experiences, today announced the expansion of its partnership with the International Internet Business Department of Xiaomi, one of the world's leading consumer electronics and smart manufacturing companies, bringing new and engaging app recommendations to Xiaomi mobile users around the world. Users purchasing new Xiaomi devices in most markets in EMEA, LATAM, APAC and MENA will enjoy premium app and mobile games recommendations delivered to the palm of their hands. Digital Turbine's technology is already delivered to over 800M devices around the world and today marks an important expansion in their global reach as the company expands its partnership with the second-largest Android phone manufacturer globally.
OTC:XIACFLong
by DEXWireNews
BZYR: Potential long term investment - with riskI've become interested in BZYR which trades only OTC at this time. Why is this OTC stock of high importance for long term investors? In order to set this out my post is broken into various parts: 1 - Introduction 2 - The historical battles 3 - Efficacy of a cancer treatment 4 - Summary 5 - The risk to reward for long term investors. The above cannot possibly avoid referring to organisations and materials in the public domain - as matters of fact and truth before the courts. Introduction: The founder has discovered a treatment for cancers that cannot be treated by conventional treatments, that is better than anything out there at this time. The research has been in the public domain for the last 30-odd years. The discovery is called Antineoplastons - which is a combination of various peptides and other 'chemicals'. Historical battles: The research evidence for efficacy has not been faulted. The FDA (in the public domain) took the founder through 4 grand juries. The case failed at the Texas State Supreme Court, in an attempt to remove the founder's medical licence. The whole story runs very deep back to the 1980s - but despite strenous efforts to shut down the treatment (and the founder), it persists to this day, through the endless legal battles. Staying within the 'House Rules' means that I am cautious not to breach. In 1982 the FDA stated " never have and never will approve a new drug to an individual but only to a large pharmaceutical firm with unlimited finances ." Therefrom sprung one of the most severe fights in FDA history. dealings with the FDA commenced in 1983 at that point the FDA commenced a civil action to try to close the clinic and stop all patients from receiving the medicine before the judge in this case. Before the judge in the 1983 court case had announced her ruling the FDA sends her a letter warning her in advance " if this court declines to grant the injunction sought by the government thus permitting continued manufacture and distribution of antineoplastons the government would then be obliged to pursue other less efficient remedies such as actions for seizure and condemnation of the drugs or criminal prosecution of individuals. " Efficacy of cancer treatment with Antineoplastons: Mainstream cancer research organisations will say " There is not enough reliable evidence to use it as a cancer treatment " or that the treatment is ' experimental '. But this is not true. If there has been an experiment, it was fully under the watch of the FDA, and the results are beyond belief for success. Double-blind randomised controlled trials in Japan have proved the superior efficacy of the treatment (which is not 100% but far better than what exists). Summary Antineoplaston treatment has weathered all battles for over 30 years. It's not going away. It's survival suggests something novel and unique has been discovered. Why is this treatment surviving at all? Why all the battles against it? Those are matters for you to ponder. The risk to reward for long term investors: The weeky chart will show that BZYR (an OTC stock) is near rock bottom and possibly in an accummulation phase. Note carefully that OTC stocks are not on conventional exchanges like NYSE and NASDAQ. The potential growth over a 5 year period could be significant in relation to a fixed risk of loss which should be an affordable one, if more research confirms it's specific kind of efficacy. This could be the next 'Amazon' of the biomedical world. As always I emphasise the risk - and I am unable to provide tips on how to manage that. Disclaimers apply.
OTC:BZYR
by Captain_Walker
MNMD Long based on Fundmntls, Lvls and MetaWorldCrypto indicatorHypothesis: pharmaceutical company price depressed due to conflict between management and investor, price artificially low due to FUD. Confluence on W1 charts: 1. Price near ATL and 2020 support levels (year of IPO), see Early 2020 Support, and 2020 Support Levels. 2. Advanced RSI in oversold band with three Regular Divergence -Bullish signals 3. Setups & Trends also showing same three Regular Divergence - Bullish signals (same signals as above) 4. StRSI <10% with K crossed up D Confluence on H1 chart 1. Price below Early 2020 and 2020 support levels and bouncing off Oct 2022 support. 2. Setup & Trend and Advanced RSI showing three Regular Divergence - Bull signals Position: Entered at $2.82 with SL at $2.70, TP1 at $3.75 Risk Management: RR 7.75, Portfolio Risk % 0.43%, SL% Loss 4.26%, TP1% Gain 32.98%
NASDAQ:MNMDLong
by metadimensional
IWMThe set up from LT support off the bottom channel has Nuked (of course) and I say that b c this year is the year where everything looks like a perfect set up that just nukes. (except oil trades) At this point IWM can still be an over throw, if small caps are pricing in all this inflation & War in Ukraine & recession talk. If the chart is to follow NQ then we have much more pain ahead. Looking at OTC stocks I am really unsure as to how much more pain can be endured. They all seem pretty bottomed. So watching for an MM overthrow here and confirmation would be working the candle sticks back into the LT channel IMO.
AMEX:IWMLong
by Big_Mike716
$DPLS entry PTs .0001-.0005 or next Spring Next Target PTs 4-17 DarkPulse, Inc., a technology-security company, develops, markets, and distributes a suite of engineering, installation, and security management solutions to industries and governments in the United States and internationally. The company's patented Brillouin optical time domain analyzer dark-pulse technology provides customer with a data stream of critical metrics for assessing the health and security of their infrastructure. It offers security platforms, including fiber optic and satellite communications services; and manufactures, sells, installs, and monitors laser sensing systems, and drone and rover systems, as well as offers oil and gas pipeline leak detection, physical security, and telecommunications and satellite communications services. The company focuses on delivering security and monitoring systems for border security, pipelines, the oil and gas industry, and mine safety applications. DarkPulse, Inc. is headquartered in New York, New York.
OTC:DPLSLong
by BADQOMOCAWGOWLD
$VYST entry PTs .0005-.002-.004 Next Target PTs .1-.15 and higheVystar Corporation manufactures and sells Vytex natural rubber latex (NRL) products to the manufacturers of rubber and rubber end products in the United States. Its products are used by manufacturers of a range of consumer and medical products, such as adhesives, gloves, balloons, condoms, and other medical devices, as well as natural rubber latex foam mattresses, toppers, and pillows. The company also offers RXair, an air purifier; and a range of residential furniture and decorative accessories. Vystar Corporation was founded in 2000 and is based in Worcester, Massachusetts.
OTC:VYSTLong
by BADQOMOCAWGOWLD
HYSR📈LETS GO BRANDON📉HYSRHey Fam.. Just an idea I wanted to share with you all about AN OTC stock with some huge potential.. Let me know what you think please add me and hit the like button if you like my idea I shared with you all.. Let me know if you have anymore Ideas you would like me to draw up I will always do my best.. Please remember.. Patience is your friend and so is the trend.. Don't fight it.. And you will be profitable with discipline and obedience..🔨🦴📉📈😉💯🎯❗🤷‍♂️
OTC:HYSRLong
by robinstallsforyou2
EPAZ attractive valuation right, under 10M. Still undiscoveredEPAZ attractive valuation right now, well under 10M market cap, with that said it should go up way higher. from here They’re launching Bitcoincredit/debit cards plus they’re in other hot sectors NFTs , CBD , Metaverse and making serious noise. EPAZ trading at such a low market cap. Most good crypto + metaverse + crypto stocks are trading at a 30M-50M market cap. Plenty of upside for $EPAZ here pretty much, it’s still very early #pennystocks #stockmarket #stocks #BTC ZenaPay Blockchain Bitcoin wallet will include credit cards/debit cards to the user wallet. The user will be able to store both fiat currency and cryptocurrency. This will be a major upgrade to the ZenaPay wallet. We are providing additional support to new cryptocurrencies. We are working towards gasless transactions and providing easy transfer to traditional bank accounts. Our primary mission is to become an alternative to bank checking accounts for businesses and allowing them to earn money from their investment into cryptocurrency. As we build out the infrastructure more opportunities will begin to arise. Epazz CEO Shaun Passley, PhD, stated, "We are creating technology for the next generation of payment solutions." Future ZenaPay upgrades to be released soon. ZenaPay (www.zenapay.com) is being developed to solve a major problem in high-risk industries. Traditional banking systems do not allow high-risk industries to access their payment systems. ZenaPay offers a cutting-edge payment solution that gives consumers a way to buy items online or in stores using Bitcoin. The new Bitcoin payment software will allow consumers to use digital currency to make online or in-store purchases with ease. The process will also be anonymous because all transaction details are encrypted through Bitcoin, which will enable stores to accept digital currency instead of only cash. ZenaPay is available on the App Store and Play Store. About Epazz, Inc. (www.epazz.com) Epazz, Inc. is a leading cloud-based-software company that specializes in providing customized cloud applications to the corporate world, higher-education institutions and the public sector. Epazz BoxesOS™ v3.0 is the complete business web-based software package for small- to mid-size businesses, Fortune 500 enterprises, government agencies and higher-education institutions. BoxesOS provides many of the web-based applications organizations would otherwise need to purchase separately. Epazz's other products are DeskFlex™ (a room scheduling software) and DeskFlex™ (an applicant-tracking system).
OTC:EPAZLong
by Bitplaza